Christos Polymeropoulos
YOU?
Author Swipe
View article: 119 Time Course of Efficacy of Ponesimod in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
119 Time Course of Efficacy of Ponesimod in Patients with Moderate-to-Severe Chronic Plaque Psoriasis Open
View article: Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial
Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial Open
Background Tasimelteon is a dual melatonin 1 and melatonin 2 receptor agonist. Tasimelteon is the first and only approved medicine to treat a circadian rhythm disorder. In this Phase III trial, the efficacy and safety of tasimelteon was st…
View article: Efficacy and safety of an alpha 7-nicotinic acetylcholine receptor agonist, VQW-765, in subjects with performance anxiety: randomised, double-blind, placebo-controlled trial
Efficacy and safety of an alpha 7-nicotinic acetylcholine receptor agonist, VQW-765, in subjects with performance anxiety: randomised, double-blind, placebo-controlled trial Open
Background Despite the high prevalence of social and performance anxiety, current treatments do not meet the full needs of patients. Development of novel anxiolytics with rapid onset of action for on-demand treatment of social and performa…
View article: 0879 Dim Light Melatonin Onset in a Delayed Sleep-Wake Phase Disorder Cohort: Ongoing Clinical Trial Update
0879 Dim Light Melatonin Onset in a Delayed Sleep-Wake Phase Disorder Cohort: Ongoing Clinical Trial Update Open
Introduction We are conducting a double-blind, randomized, clinical study in Delayed Sleep-Wake Phase Disorder (DSWPD) participants with extensive clinical phenotyping. We evaluated screening Dim Light Melatonin Onset (DLMO) assessments in…
View article: Motion Syros: tradipitant effective in the treatment of motion sickness; a multicenter, randomized, double-blind, placebo-controlled study
Motion Syros: tradipitant effective in the treatment of motion sickness; a multicenter, randomized, double-blind, placebo-controlled study Open
Introduction Motion sickness has afflicted travelers since ancient times. Neurokinin-1 (NK1) receptor antagonists have therapeutic potential as treatments for the symptoms of motion sickness due to the widespread expression of NK1 receptor…
View article: An Association of SLC2A9 variant rs7442295 with Uric Acid at Baseline and in Interaction with Iloperidone
An Association of SLC2A9 variant rs7442295 with Uric Acid at Baseline and in Interaction with Iloperidone Open
Uric acid concentrations are routinely measured during clinical laboratory evaluations, given serum urate levels correlate with blood pressure, metabolic syndrome, diabetes, gout, and cardiovascular disease. Circulating levels of uric acid…
View article: Screening effects of HCN channel blockers on sleep/wake behavior in zebrafish
Screening effects of HCN channel blockers on sleep/wake behavior in zebrafish Open
Hyperpolarization-activated cyclic nucleotide-gated (HCN) ion channels generate electrical rhythmicity in various tissues although primarily heart, retina and brain. The HCN channel blocker compound, Ivabradine (Corlanor), is approved by t…
View article: The Efficacy of Tradipitant in Patients With Diabetic and Idiopathic Gastroparesis in a Phase 3 Randomized Placebo-Controlled Clinical Trial
The Efficacy of Tradipitant in Patients With Diabetic and Idiopathic Gastroparesis in a Phase 3 Randomized Placebo-Controlled Clinical Trial Open
View article: Efficacy and Safety of Iloperidone in Bipolar Mania
Efficacy and Safety of Iloperidone in Bipolar Mania Open
Trial Registration: ClinicalTrials.gov identifier: NCT04819776; EudraCT: 2020-000405-83.
View article: Corrigendum: Case report: A patient with Delayed Sleep-Wake Phase Disorder and Optic Nerve Hypoplasia treated with tasimelteon: a case study
Corrigendum: Case report: A patient with Delayed Sleep-Wake Phase Disorder and Optic Nerve Hypoplasia treated with tasimelteon: a case study Open
[This corrects the article DOI: 10.3389/fnins.2023.1287514.].
View article: Case report: A patient with Delayed Sleep-Wake Phase Disorder and Optic Nerve Hypoplasia treated with tasimelteon: a case study
Case report: A patient with Delayed Sleep-Wake Phase Disorder and Optic Nerve Hypoplasia treated with tasimelteon: a case study Open
We present a case of an adult female diagnosed with Delayed Sleep-Wake Phase Disorder (DSWPD) and Optic Nerve Hypoplasia (ONH), with a confirmed delayed Dim Light Melatonin Onset (DLMO), who reports the inability to fall asleep at their de…
View article: Screening effects of HCN channel blockers on sleep/wake behavior in zebrafish
Screening effects of HCN channel blockers on sleep/wake behavior in zebrafish Open
Hyperpolarization-activated cyclic nucleotide-gated (HCN) ion channels generate electrical rhythmicity in various tissues although primarily heart, retina and brain. The HCN channel blocker compound, Ivabradine (Corlanor), is approved by t…
View article: 0642 Effect of Iloperidone on Sleep Symptoms in Bipolar Patients with Manic and Mixed Episodes: A Randomized, Placebo Controlled Study
0642 Effect of Iloperidone on Sleep Symptoms in Bipolar Patients with Manic and Mixed Episodes: A Randomized, Placebo Controlled Study Open
Introduction Iloperidone, a dopamine D2 receptor and serotonin 5HT2A receptor antagonist, was evaluated for the treatment of acute manic and mixed episodes associated with bipolar I disorder in adults in a phase 3 clinical trial. A core sy…
View article: 0620 Dim Light Melatonin Onset Analysis in Individuals Diagnosed with Delayed Sleep-Wake Phase Disorder (DSWPD)
0620 Dim Light Melatonin Onset Analysis in Individuals Diagnosed with Delayed Sleep-Wake Phase Disorder (DSWPD) Open
Introduction We are conducting a double-blind, randomized, clinical study in Delayed Sleep-Wake Phase Disorder (DSWPD) participants with extensive clinical phenotyping. We evaluated screening Dim Light Melatonin Onset (DLMO) assessments in…
View article: Tradipitant effective in the reduction of vomiting associated with motion sickness across varied sea conditions
Tradipitant effective in the reduction of vomiting associated with motion sickness across varied sea conditions Open
View article: Hispanics taking tradipitant for motion sickness have a lower incidence of vomiting as compared to non-hispanics
Hispanics taking tradipitant for motion sickness have a lower incidence of vomiting as compared to non-hispanics Open
View article: Case report: A novel missense variant in melanopsin associates with delayed sleep phenotype: Whole genome sequencing study
Case report: A novel missense variant in melanopsin associates with delayed sleep phenotype: Whole genome sequencing study Open
Melanopsin (OPN4) is a blue light-sensitive opsin-type G-protein coupled receptor. It is highly expressed in photosensitive retinal ganglion cells which mediate responses to light, including regulation of sleep, circadian photoentrainment,…
View article: Once-daily tasimelteon (VEC-162) for jet lag following transmeridian travel: A multicenter, randomized, double-blind, placebo-controlled trial
Once-daily tasimelteon (VEC-162) for jet lag following transmeridian travel: A multicenter, randomized, double-blind, placebo-controlled trial Open
Jet Lag Disorder is a Circadian Rhythm Sleep-Wake Disorder resulting from a misalignment of the endogenous circadian clock and the sleep and wake pattern required by a change in time zone. Jet lag is most severe following eastward travel. …
View article: Enrichment of Motilin Receptor Loss-of-Function Variants in Gastroparesis
Enrichment of Motilin Receptor Loss-of-Function Variants in Gastroparesis Open
Introduction: Gastroparesis is a serious medical condition characterized by delayed gastric emptying and symptoms of nausea, vomiting, bloating, fullness after meals, and abdominal pain. Methods: To ascertain the genetic risk factors for g…
View article: Elevated plasma levels of CXCL16 in severe COVID-19 patients
Elevated plasma levels of CXCL16 in severe COVID-19 patients Open
Genome-wide association studies have recently identified 3p21.31, with lead variant pointing to the CXCR6 gene, as the strongest thus far reported susceptibility risk locus for severe manifestation of COVID-19. In order the determine its r…
View article: An observational study investigating the CRY1Δ11 variant associated with delayed sleep–wake patterns and circadian metabolic output
An observational study investigating the CRY1Δ11 variant associated with delayed sleep–wake patterns and circadian metabolic output Open
View article: Elevated plasma levels of CXCL16 in severe COVID-19 patients
Elevated plasma levels of CXCL16 in severe COVID-19 patients Open
Genome-wide association studies have recently identified 3p21.31, with lead variant pointing to the CXCR6 gene, as the strongest thus far reported susceptibility risk locus for severe manifestation of COVID-19. In order the determine its r…
View article: Loss-of-function mutations in IFNAR2 in COVID-19 severe infection susceptibility
Loss-of-function mutations in IFNAR2 in COVID-19 severe infection susceptibility Open
View article: An Observational Study Investigating the CRY1Δ11 Variant Associated with Delayed Sleep-wake Patterns and Circadian Metabolic Output
An Observational Study Investigating the CRY1Δ11 Variant Associated with Delayed Sleep-wake Patterns and Circadian Metabolic Output Open
We conducted an observational research study to collect information on sleep-wake patterns from participants with a confirmed status of the cryptochrome circadian clock 1 (CRY1) splicing variant, CRY1Δ11 c.1657+3A>C, and their controls, de…
View article: Genomic and phenotypic characterization of Investigator Global Assessment (IGA) scale-based endotypes in atopic dermatitis
Genomic and phenotypic characterization of Investigator Global Assessment (IGA) scale-based endotypes in atopic dermatitis Open
View article: Neurokinin‐1 receptor antagonist tradipitant has mixed effects on itch in atopic dermatitis: results from EPIONE, a randomized clinical trial
Neurokinin‐1 receptor antagonist tradipitant has mixed effects on itch in atopic dermatitis: results from EPIONE, a randomized clinical trial Open
Atopic dermatitis (AD) is a relapsing and remitting disease characterized by intense pruritus that can lead to scratching and eczematous lesions that vary in extent and severity.1 Over 60% of AD cases are mild, characterized by slight eryt…
View article: Tradipitant in the Treatment of Motion Sickness: A Randomized, Double-Blind, Placebo-Controlled Study
Tradipitant in the Treatment of Motion Sickness: A Randomized, Double-Blind, Placebo-Controlled Study Open
Introduction: Novel therapies are needed for the treatment of motion sickness given the inadequate relief and bothersome and dangerous adverse effects of currently approved therapies. Neurokinin-1 (NK1) receptor antagonists have the…
View article: Efficacy of Tasimelteon (HETLIOZ®) in the Treatment of Jet Lag Disorder Evaluated in an 8-h Phase Advance Model; a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Efficacy of Tasimelteon (HETLIOZ®) in the Treatment of Jet Lag Disorder Evaluated in an 8-h Phase Advance Model; a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Open
Background: Most travelers experience Jet Lag Disorder (JLD) symptoms due to misalignment of their circadian rhythms with respect to the new time zone. We assessed the efficacy and safety of tasimelteon (HETLIOZ®) in healthy partici…
View article: Neurokinin-1 receptor antagonist tradipitant improves itch associated with mild atopic dermatitis: Results from EPIONE a randomized clinical trial
Neurokinin-1 receptor antagonist tradipitant improves itch associated with mild atopic dermatitis: Results from EPIONE a randomized clinical trial Open
Importance Safe oral systemic treatments are needed to treat itch associated with atopic dermatitis (AD). Objective To examine the efficacy and safety of tradipitant, a neurokinin-1 receptor antagonist, in adults with mild to severe AD. De…
View article: Direct ACE2- Spike RBD Binding Disruption with Small Molecules: A Strategy for COVID-19 Treatment
Direct ACE2- Spike RBD Binding Disruption with Small Molecules: A Strategy for COVID-19 Treatment Open
ACE2 is a key receptor for SARS-CoV-2 cell entry. Binding of SARS-Cov-2 to ACE2 involves the viral Spike protein. The molecular interaction between ACE2 and Spike has been resolved. Interfering with this interaction might be used in treati…